Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBITDA (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed EBITDA for 11 consecutive years, with -$19.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 23.92% to -$19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$94.0 million through Dec 2025, down 69196.32% year-over-year, with the annual reading at $5.7 million for FY2025, 4088.24% up from the prior year.
  • EBITDA hit -$19.4 million in Q4 2025 for Seres Therapeutics, up from -$22.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $88.8 million in Q3 2024 to a low of -$71.2 million in Q1 2023.
  • Historically, EBITDA has averaged -$26.2 million across 5 years, with a median of -$37.8 million in 2021.
  • Biggest five-year swings in EBITDA: surged 325.29% in 2021 and later tumbled 187.76% in 2022.
  • Year by year, EBITDA stood at -$50.1 million in 2021, then crashed by 37.18% to -$68.7 million in 2022, then soared by 39.95% to -$41.2 million in 2023, then skyrocketed by 62.09% to -$15.6 million in 2024, then fell by 23.92% to -$19.4 million in 2025.
  • Business Quant data shows EBITDA for MCRB at -$19.4 million in Q4 2025, -$22.5 million in Q3 2025, and -$24.9 million in Q2 2025.